BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, September 10, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
9/7
cls
|
|
Addex
Therapeutics Ltd. (SIX:ADXN)
|
Wedbush
|
Christopher
Marai
|
New
|
Outperform
|
21%
|
CHF9.20
|
|
Marai
set a CHF28 target. He believes the "primary value driver" for
Addex is a potential near-term partnership for dipraglurant-IR. The
immediate-release formulation of a negative allosteric modulator of
metabotropic glutamate receptor subtype 5 (mGluR5) is in Phase II testing to
treat Parkinson's disease levodopa-induced dyskinesia (PD-LID). Marai
anticipates a partnership by year end or 1H13. He believes peak dipraglurant
sales in PD-LID and other indications could exceed $1.5B.
|
|
ImmunoCellular
Therapeutics Ltd. (NYSE-M:IMUC)
|
Maxim
Group
|
Jason
Kolbert
|
New
|
Buy
|
23%
|
$3.17
|
|
Kolbert
set an $18 target on the belief that ImmunoCellular has the potential to
create a second-generation dendritic cancer vaccine that addresses "perceived
shortfalls" of prostate cancer vaccine Provenge sipuleucel-T from Dendreon
Corp. (NASDAQ:DNDN), including high manufacturing costs. ImmunoCellular's
lead product ICT-107 is an intradermal tumor associated antigen-pulsed
dendritic cell-based therapeutic vaccine in Phase II testing to treat
glioblastoma multiforme (GBM). Kolbert anticipates Phase II data in 2H13,
followed by approval in the EU in 2014 and in the U.S. in 2018. He estimates
ICT-107 sales could reach $2.3B in 2022.
|
192
words displayed of
680
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]